Abstract
EGFR overexpression in gastric cancer (GC) has been reported in about 30% of patients. However, the anti-EGFR antibodies cetuximab and panitumumab have failed to improve overall survival of GC patients in combination with cytotoxic chemotherapy compared with chemotherapy alone. GC1118, a novel anti-EGFR antibody with a distinct binding epitope compared with cetuximab or panitumumab, has not been tested in GC. GC cell lines, SNU-1, SNU-5, SNU-16, SNU-216, SNU-484, SNU-601, SNU-620, SNU-638, SNU-668, SNU-719, AGS, MKN-45, NCI-N87, and KATO-III, were employed to test the effect of cetuximab or GC1118 alone, and combined with the cytotoxic agent cisplatin or 5-fluorouracil (5-FU). Cells were also treat with or without high-affinity ligands EGF 20 ng/ml or HB-EGF 100 ng/ml. GC1118 exhibited a more potent growth inhibition effect in the majority of cell lines than cetuximab in MTT assay, regardless of the KRAS mutation status of cell lines. Co-treatment of GC1118 and cisplatin or 5-FU inhibited colony formation and migration to a greater extent, even following EGFR ligand stimulation. Ligand-induced p-AKT and p-ERK upregulation were more potently inhibited by combination treatment with GC1118 and chemotherapeutic agents compared with...Continue Reading
References
Feb 9, 2008·Cellular and Molecular Life Sciences : CMLS·M J Wieduwilt, M M Moasser
Apr 10, 2008·Histopathology·M A KimW H Kim
Oct 21, 2011·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Birgit HotzHubert G Hotz
Feb 1, 2012·Journal of Cancer Research and Clinical Oncology·Stefan HeindlBirgit Luber
Feb 9, 2012·Nature Medicine·Alberto Bardelli, Pasi A Jänne
Feb 9, 2012·Gut·Niantao DengPatrick Tan
May 16, 2012·Cancer Discovery·Andrea BertottiLivio Trusolino
Jun 1, 2012·BMC Cancer·Takaya ShimuraTakashi Joh
Jun 23, 2012·Nature·Sandra MisaleAlberto Bardelli
Jul 13, 2012·Nature Reviews. Cancer·Yosef Yarden, Gur Pines
Jul 17, 2012·Oncogene·S KasperM Schuler
Apr 19, 2013·The Lancet Oncology·Florian LordickUNKNOWN Arbeitsgemeinschaft Internistische Onkologie and EXPAND Investigators
Apr 19, 2013·The Lancet Oncology·Tom WaddellYolanda Barbachano
Apr 30, 2014·BMC Research Notes·Naoki TakahashiYasuhiro Shimada
Dec 17, 2014·Nature Communications·Sharmistha ChakrabortyAmyn A Habib
Nov 21, 2015·Molecular Cancer Therapeutics·Yangmi LimJonghwa Won
Feb 5, 2016·Science Translational Medicine·Sabrina ArenaAlberto Bardelli
May 3, 2016·Nature Medicine·Chiara PozziMaria Rescigno
Nov 3, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sumita TrivediRobert L Ferris
Sep 30, 2016·British Journal of Cancer·L MarziC Gongora
Oct 25, 2016·Oncogene·A Dokala, S S Thakur
Dec 10, 2016·Journal of Cancer Research and Clinical Oncology·Julia KneisslBirgit Luber
Jun 9, 2017·Nature Communications·Moiez AliKris C Wood
Oct 17, 2017·Nature Medicine·Yuanyuan LuRobert J Coffey
Citations
Nov 28, 2019·International Journal of Molecular Sciences·Hye Won LeeDo-Hyun Nam
Mar 17, 2020·Frontiers in Pharmacology·Hui XieLuo Gu
Nov 5, 2020·Cancers·Kyoungmin LeeDo-Hyun Nam